SCHEMBL17239108

SCHEMBL17239108

O=S(=O)(O)CCO.O=S(=O)(O)CCS(=O)(=O)O

nearest known ligand 0.47

Known targets — ChEMBL curated mechanism

DRD2

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.47
BLM P54132 2/20 0.47
PTGS1 P23219 1/20 0.47
PDE4A P27815 1/20 0.47
SLC6A6 P31641 1/20 0.47
CYP2C19 P33261 1/20 0.47
APP P05067 1/20 0.43
POLB P06746 3/20 0.36
ALDH1A1 P00352 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 1/20 0.36
ALOX15 P16050 1/20 0.36
BRCA1 P38398 1/20 0.36
HTT P42858 1/20 0.36
GMNN O75496 1/20 0.36
PKM P14618 1/20 0.36
THPO P40225 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249947 0.96 LMNA (0.50) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL827 0.96
SCHEMBL9001614 0.93
SCHEMBL4306610 0.93
SCHEMBL1457944 0.93
SCHEMBL11516591 0.93 LMNA (0.47) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL8780216 0.93 LMNA (0.47) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL1304651 0.93
Bromide SCHEMBL20595015 0.93
SCHEMBL1138826 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102947305-B Compounds and methods for kinase modulation and indications therefor 普莱希科公司 2016-07-06 CN disclosed
US-20150320718-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS PHARMACYCLICS LLC 2015-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320718-A1 NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS HDAC1, HDAC3, HDAC5 LMNA 2695/4885BLM 4261/4885PTGS1 1439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.